



## PRESS RELEASE

### Therillia Names Dr. Pierre Beauparlant Chief Business Officer

**Montreal – Dec. 5<sup>th</sup>, 2016** – Therillia Development Company Inc., a Sanderling Ventures portfolio company, announced today the appointment of Dr. Pierre Beauparlant as Chief Business Officer. He will be responsible for the development and execution of business strategy for Therillia, as well as the development stage pharmaceutical companies that Therillia manages. Initially, Dr. Beauparlant’s efforts will focus on [Diazon Pharmaceuticals](#), a preclinical stage company developing DZ-2384, a novel onco-therapeutic agent, for the treatment of multiple different cancers.

“Pierre has more than 19 years of significant experience in large pharma and development stage, venture backed biopharmaceutical companies. He brings broad expertise from discovery through commercialization,” said Michael Dixon, President and CEO of Therillia. “Pierre’s extensive experience in all aspects of the drug development business in different settings will be extremely valuable to Diazon and Therillia’s other companies in our portfolio.”

“Sanderling Ventures is committed to the development of sustainable bio-pharmaceutical companies in Quebec,” said Robert McNeil, Managing Director of Sanderling Ventures and Chairman of Therillia. “Finding and retaining experienced leadership like Pierre is an essential element of our success. The addition of Dr. Beauparlant to Therillia is an important step in that direction.”

Dr. Beauparlant most recently served as Medical Therapeutic Head – Hematology at Novartis Pharmaceuticals Canada. During his work at Novartis, Pierre oversaw 46 clinical trials and supported Drug Regulatory Affairs and Market Access departments in their submissions to regulatory authorities. Prior to Novartis, Dr. Beauparlant held roles of increasing responsibility at Gemin X Pharmaceuticals Inc., a venture-backed clinical stage oncology company sold to Cephalon in 2011. As Vice President Research and Scientific Development, he held responsibilities for advancing drug discovery projects to identify new chemical entities for the treatment of cancer, business development, in-licensing, and intellectual property.

Dr. Beauparlant received his Ph.D. degree in Microbiology & Immunology from McGill University, as well as M.Sc. and B.Sc. degrees from University of Montreal.

“I am excited to join the Therillia team and contribute to the success of the early stage companies that it manages,” said Dr. Beauparlant. “Therillia is well positioned for success with Diazon and its other companies, with a vision to develop and advance these novel projects to commercially viable products.”



### **About Therillia Development Company Inc.**

Therillia Development Company Inc. is an autonomous portfolio company of Sanderling Ventures located in Montreal. Its mandate is to cost-effectively develop novel drug candidates of interest to Sanderling and other venture capital investors from preclinical to clinical proof of concept. Central to this mission is the deployment of scientific platforms to support the proof of concept strategies by identifying potential responder patient populations, rational drug combinations, and the utility of clinical biomarkers. By utilizing an experienced team of drug developers over multiple projects, Therillia will significantly reduce the time and cost of achieving proof of concept data for important new therapeutics. Ultimately, drug candidates successfully developed by Therillia will result in new sustainable biopharmaceutical companies in Quebec.

<http://www.therillia.com/mission-statement/>

### **About Sanderling Ventures**

Sanderling Ventures is among the oldest investment firms dedicated to building new biomedical companies. Sanderling emphasizes early-stage financing and active management of its portfolio companies. Its principals play an active role in new ventures by providing seed and early-stage funding, contributing management leadership and administrative support, developing cost-control strategies to extend available dollars, supplying technical and regulatory expertise where needed, and offering the insight and perspective of those who have “done it before.”

<http://www.sanderling.com>

### **About Diazon Pharmaceuticals Inc.**

Diazon Pharmaceuticals, a Montreal based company, is developing the onco-therapeutic DZ-2384 that targets a proven therapeutic pathway in oncology, but one whose potential in modern cancer therapy has been severely restricted due to unacceptable toxicities. DZ-2384 overcomes this restriction by modulating microtubule structure and dynamics in a distinct way, delivering potent anti-tumor efficacy with a superior safety profile. The company was founded in 2013 by researchers at UCLA and McGill University.

<http://www.diazonpharmaceuticals.com/>

### **For more information, contact**

Michael Dixon

President and CEO

Therillia Development Company Inc.

Tel.: 514-564-6474 x222

[info@therillia.com](mailto:info@therillia.com)